UK – NICE nod for Lilly’s breast cancer drug Verzenio via CDF

Helps Lilly drug in pursuit of Ibrance and Kisqali. Thousands of women with advanced breast cancer could get access to treatment with Eli Lilly’s CDK 4/6 inhibitor Verzenio, after NICE backed its use via the Cancer Drugs Fund (CDF).

The cost-effectiveness watchdog has opted to make Verzenio (abemaciclib) plus fulvestrant available to around 4,800 women with hormone receptor (HR) positive, HER2-negative breast cancer which has spread to other parts of the body, provided they have already received endocrine treatment.

The approval sets Verzenio up as a second-line option after other drugs in the CDK 4/6 inhibitor class – including Verzenio itself as well as Novartis’ Kisqali (ribociclib) and Pfizer’s Ibrance (palbociclib) – which have previously been approved for first-line use in HR-positive, HER2-negative advanced breast cancer.

Professor Andrew Wardley, director of systemic anticancer therapy at The Christie NHS Foundation Trust, said the CDK 4/6 inhibitors are a “major improvement in the treatment of breast cancer” and the new combination “will allow more people to benefit from an effective treatment and offer more choice to others.”…